ARCHIVES

Study Finds No Benefit for Frequent CA125 Testing in Recurrent Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 35 No. 22 | June 5, 2009

Download PDF Visit The Full Archive

Related Articles

Sen. Mack Calls For “National Crusade” Against Cancer.

May 26, 2000

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

July 13, 2007

Vasopermeation Technology Awarded Patent For CA Firm.

September 28, 2001

FDA Approves Bexxar For Treatment Of Non-Hodgkin’s Lymphoma.

July 4, 2003

Advocacy. Bypass Budget Treated As Serious Funding Request By Advocates

January 30, 1998

US Preventive Services Task Force To Downgrade PSA Screening From “I” to “D” — As In “Don’t Do it.”

October 6, 2011